Non-Alcoholic Fatty Liver Disease (NAFLD) affects a large proportion of the global adult population, but there’s no agreement on how to treat it.
Omega-3 fatty acids have been shown to be beneficial in the treatment of hyperlipidemia and cardiovascular disease, and have recently been proposed as a treatment for NAFLD.
Omega-3 fatty acids are important transcriptional regulators of hepatic genes.
Clinical studies show that they reduce hepatic steatosis, improve insulin sensitivity, and lower inflammation markers.
Human clinical trials generally confirm these findings but have significant design flaws.
Huang, T.DS., Behary, J. and Zekry, A. 2019. Non-alcoholic fatty liver disease (NAFLD): a review of epidemiology, risk factors, diagnosis, and management. 10.1111/imj.14709.
How was the experience with article?
We'd love to know!